On September 21, 2021 Eli Lilly and Company (NYSE: LLY) reported the early tender results of its previously announced cash tender offer for specified series of its outstanding debt securities (Press release, Eli Lilly, SEP 21, 2021, View Source [SID1234590111]). Lilly also announced that it has removed the previously announced note caps setting forth the maximum principal amounts of its 4.150% Notes due 2059 and its 3.950% Notes due 2049 that Lilly will accept for purchase pursuant to the tender offer. Except as described in this press release, all other terms of the tender offer as described in the Offer to Purchase, dated September 7, 2021 (the "Offer to Purchase"), and the related Letter of Transmittal remain unchanged.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A total of $2,016,575,000 in aggregate principal amount of the notes listed in the table below were validly tendered and not validly withdrawn on or before 5:00 p.m., New York City time, on September 20, 2021, the early tender date for the tender offer. The table below sets forth the aggregate principal amount of each series of notes subject to the tender offer that was validly tendered and not validly withdrawn on or prior to the early tender date.
Title of Security
CUSIP No.
Acceptance Priority Level
Principal Amount Outstanding
Principal Amount Tendered
Approximate Percentage of Outstanding Amount Tendered
Anticipated Principal Amount to be Accepted for Purchase
4.150% Notes due 2059
532457 BU1
1(1)
$1,000,000,000
$408,714,000
40.87%
$408,714,000
3.950% Notes due 2049
532457 BT4
2(2)
$1,500,000,000
$541,847,000
36.12%
$541,847,000
7.125% Notes due 2025
532457 AM0
3
$229,692,000
$12,221,000
5.32%
$12,221,000
6.770% Notes due 2036
532457 AP3
4
$174,445,000
$15,880,000
9.10%
$15,880,000
5.950% Notes due 2037
532457 BC1
5
$284,112,000
$17,284,000
6.08%
$17,284,000
5.550% Notes due 2037
532457 BA5
6
$476,152,000
$31,420,000
6.60%
$31,420,000
5.500% Notes due 2027
532457 AZ1
7
$377,505,000
$13,181,000
3.49%
$13,181,000
4.650% Notes due 2044
532457 BG2
8
$43,016,000
$4,680,000
10.88%
$4,680,000
3.950% Notes due 2047
532457 BR8
9
$436,129,000
$89,177,000
20.45%
$89,177,000
3.875% Notes due 2039
532457 BS6
10
$360,745,000
$120,492,000
33.40%
$120,492,000
3.700% Notes due 2045
532457 BJ6
11
$412,467,000
$25,668,000
6.22%
$25,668,000
3.375% Notes due 2029
532457 BV9
12
$1,150,000,000
$369,771,000
32.15%
$219,436,000
3.100% Notes due 2027
532457 BP2
13
$401,450,000
$54,408,000
13.55%
$0
2.750% Notes due 2025
532457 BH0
14
$560,646,000
$146,108,000
26.06%
$0
2.350% Notes due 2022
532457 BQ0
15
$750,000,000
$165,724,000
22.10%
$0
(1)
Lilly has removed the previously announced note cap setting forth the maximum principal amount of 4.150% Notes due 2059 that Lilly will accept for purchase pursuant to the tender offer.
(2)
Lilly has removed the previously announced note cap setting forth the maximum principal amount of 3.950% Notes due 2049 that Lilly will accept for purchase pursuant to the tender offer.
Subject to the conditions in the Offer to Purchase, notes validly tendered and not validly withdrawn at or prior to the early tender date with Acceptance Priority Level 12 have been accepted for purchase using a proration factor of approximately 59.4%.
The settlement date for the notes accepted for purchase by Lilly in connection with the early tender date is currently expected to be September 22, 2021.
Lilly expects to determine the pricing terms of the tender offer at 10:00 a.m., New York City time, on September 21, 2021, unless extended. The tender offer is scheduled to expire at 11:59 p.m., New York City time, on October 4, 2021, unless extended or terminated earlier.
Holders of notes subject to the tender offer who validly tendered and did not validly withdraw their notes on or prior to the early tender date are eligible to receive the applicable total consideration, which includes an early tender premium of $30 per $1,000 principal amount of notes validly tendered by such holders that are accepted for purchase by Lilly. Accrued and unpaid interest from the last interest payment date for the applicable series of notes to, but excluding, the applicable settlement date will be paid in cash in respect of all validly tendered notes accepted for purchase by Lilly in the tender offer.
In accordance with the terms of the tender offer, the withdrawal date was 5:00 p.m., New York City time, on September 20, 2021. As a result, tendered notes may no longer be withdrawn, except in certain limited circumstances where additional withdrawal rights are required by law.
The tender offer is being conducted on the terms and subject to the conditions set forth in the Offer to Purchase and the related Letter of Transmittal, as supplemented by this press release.
Lilly has retained BofA Securities, Inc. and Citigroup Global Markets Inc. to serve as lead dealer managers for the tender offer, and Barclays Capital, Inc., BNP Paribas Securities Corp. and Deutsche Bank Securities Inc. to serve as co-dealer managers. Lilly has retained Global Bondholder Services Corporation to serve as tender agent and information agent for the tender offer.
Requests for documents relating to the tender offer may be directed to Global Bondholder Services Corporation by telephone at +1 (866) 470-3900, by email at [email protected] or in writing at 65 Broadway, Suite 404, New York, NY 10006. Questions regarding the tender offer may be directed to BofA Securities, Inc. toll-free at +1 (888) 292-0070 or collect at +1 (980) 387-3907 or to Citigroup Global Markets Inc. toll-free at +1 (800) 558-3745 or collect +1 (212) 723-6106.
This press release is for informational purposes only and is not an offer to purchase, the solicitation of an offer to sell any notes. The tender offer is being made only pursuant to the Offer to Purchase and the information in this press release is qualified by reference to the Offer to Purchase. In any jurisdiction where the laws require the tender offer to be made by a licensed broker or dealer, the tender offer will be deemed made on behalf of Lilly by the dealer managers, or one or more registered brokers or dealers under the laws of such jurisdiction. None of Lilly or its affiliates, their respective boards of directors, the Dealer Managers, Global Bondholder Services Corporation or the trustee with respect to any series of notes is making any recommendation as to whether holders should tender any notes in response to the tender offer, and neither Lilly nor any such other person has authorized any person to make any such recommendation. Holders must make their own decision as to whether to tender any of their notes, and, if so, the principal amount of notes to tender.
In addition, this press release is not an offer to sell or the solicitation of an offer to buy any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any such securities will be offered only by means of a prospectus, including a prospectus supplement relating to such securities, meeting the requirements of Section 10 of the Securities Act of 1933, as amended.